The estimated Net Worth of James F. Dempsey is at least $587 Tysiąc dollars as of 24 October 2022. Dr Dempsey owns over 167,000 units of ViewRay stock worth over $19,484 and over the last 8 years he sold VRAY stock worth over $44,410. In addition, he makes $523,085 as Chief Scientific Officer at ViewRay.
Dr has made over 5 trades of the ViewRay stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 167,000 units of VRAY stock worth $125,250 on 24 October 2022.
The largest trade he's ever made was exercising 279,414 units of ViewRay stock on 3 September 2019 worth over $190,002. On average, Dr trades about 45,702 units every 140 days since 2017. As of 24 October 2022 he still owns at least 779,368 units of ViewRay stock.
You can see the complete history of Dr Dempsey stock trades at the bottom of the page.
Dr. James F. Dempsey is the Chief Scientific Officer at ViewRay.
As the Chief Scientific Officer of ViewRay, the total compensation of Dr Dempsey at ViewRay is $523,085. There are 1 executives at ViewRay getting paid more, with Scott William Drake having the highest compensation of $1,406,115.
Dr Dempsey is 50, he's been the Chief Scientific Officer of ViewRay since . There are 2 older and 2 younger executives at ViewRay. The oldest executive at ViewRay Inc. is Robert Michael Fuchs, 54, who is the Chief HR Officer.
James's mailing address filed with the SEC is C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER, CO, 80202.
Over the last 8 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun oraz Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: